Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06627738 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost

Study acronym: Cybertaxcis II
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jun 2033 to Feb 2034
    • Enrollment target: 37 to 42
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: 7 to 5
    v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Mar 2033 to Jun 2033
    • Start date changed from estimate of Jun 2025 to Jun 10, 2025
    • Site details revised
    v4
  3. Start date: Jan 2025 to Jun 2025v3
  4. Eligibility criteria shortened, about 8 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a monocentric, non-randomized, open-label, superiority phase II clinical investigation evaluating the efficacy of additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in patients with locally advanced non-small cell lung carcinoma (NSCLC), with an interim analysis.
Trial Details
NCT Number NCT06627738
Lead Sponsor Centre Antoine Lacassagne
Conditions
(from sponsor)		 Carcinoma, Non-Small-Cell Lung
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov